Skip to main content
Premium Trial:

Request an Annual Quote

BC Platforms Lands $10 Million Investment From Debiopharm, Tesi

CHICAGO (GenomeWeb) – BC Platforms, a Swiss genomic data management company, announced today that it has raised $10 million in a Series B funding round. The Debiopharm Innovation Fund, of Lausanne, Switzerland, and Finnish private equity company Tesi led the investment.

BC Platforms said it plans on using the funding in part to add a clinical component this year to its existing software for genomic data management. The company has a goal of managing genomic and clinical data of at least 5 million people by 2020, drawn from biobanks around the world.

"We see big data as a core asset in research and development. We are excited to have invested in BC Platforms and look forward to working with them to unlock the potential of big data to dramatically improve R&D productivity and provide clinical benefits to patients," Tanja Dowe, head of Debiopharm Innovation Fund, said in a statement.

"This funding will enable us to progress to our next stage of expansion and to launch our new knowledge-based solutions for R&D customers worldwide," added BC Platforms CEO Tero Silvola. "Debiopharm’s experience in drug development will provide us with invaluable insight as we launch this major new initiative."

BC Platforms has forged partnerships with numerous biobanks, including Codigo46 in Mexico and Auria Biobank in Finland. It is participating in at least nine European Union-sanctioned genomics efforts.